Combined PET and Biopsy Evidence of Marrow Involvement Improves Prognostic Prediction in Diffuse Large B-Cell Lymphoma

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Bone marrow is an important extranodal site in diffuse large B-cell lymphoma (DLBCL), and marrow histology has been incorporated into the new National Comprehensive Cancer Network international prognostic index. Marrow involvement demonstrated histologically confers poor prognosis but is identified by staging PET in more cases. How information from staging PET and biopsy should be combined to optimize outcome prediction remains unclear.

Related collections

Most cited references 21

Record: found
Abstract: not found
Article: not found

Regression Models and Life-Tables

D R Cox (1972)

0 comments Cited 1607 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Revised response criteria for malignant lymphoma.

Bruce D Cheson, Beate Pfistner, Malik Juweid … (2007)

Standardized response criteria are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies. The International Working Group response criteria (Cheson et al, J Clin Oncol 17:1244, 1999) were widely adopted, but required reassessment because of identified limitations and the increased use of [18F]fluorodeoxyglucose-positron emission tomography (PET), immunohistochemistry (IHC), and flow cytometry. The International Harmonization Project was convened to provide updated recommendations. New guidelines are presented incorporating PET, IHC, and flow cytometry for definitions of response in non-Hodgkin's and Hodgkin's lymphoma. Standardized definitions of end points are provided. We hope that these guidelines will be adopted widely by study groups, pharmaceutical and biotechnology companies, and regulatory agencies to facilitate the development of new and more effective therapies to improve the outcome of patients with lymphoma.

0 comments Cited 468 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project.

JR Andersen, MA Shipp, DP Harrington … (1993)

Although many patients with intermediate-grade or high-grade (aggressive) non-Hodgkin's lymphoma are cured by combination chemotherapy, the remainder are not cured and ultimately die of their disease. The Ann Arbor classification, used to determine the stage of this disease, does not consistently distinguish between patients with different long-term prognoses. This project was undertaken to develop a model for predicting outcome in patients with aggressive non-Hodgkin's lymphoma on the basis of the patients' clinical characteristics before treatment. Adults with aggressive non-Hodgkin's lymphoma from 16 institutions and cooperative groups in the United States, Europe, and Canada who were treated between 1982 and 1987 with combination-chemotherapy regimens containing doxorubicin were evaluated for clinical features predictive of overall survival and relapse-free survival. Features that remained independently significant in step-down regression analyses of survival were incorporated into models that identified groups of patients of all ages and groups of patients no more than 60 years old with different risks of death. In 2031 patients of all ages, our model, based on age, tumor stage, serum lactate dehydrogenase concentration, performance status, and number of extranodal disease sites, identified four risk groups with predicted five-year survival rates of 73 percent, 51 percent, 43 percent, and 26 percent. In 1274 patients 60 or younger, an age-adjusted model based on tumor stage, lactate dehydrogenase level, and performance status identified four risk groups with predicted five-year survival rates of 83 percent, 69 percent, 46 percent, and 32 percent. In both models, the increased risk of death was due to both a lower rate of complete responses and a higher rate of relapse from complete response. These two indexes, called the international index and the age-adjusted international index, were significantly more accurate than the Ann Arbor classification in predicting long-term survival. The international index and the age-adjusted international index should be used in the design of future therapeutic trials in patients with aggressive non-Hodgkin's lymphoma and in the selection of appropriate therapeutic approaches for individual patients.

0 comments Cited 425 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Journal

Title: Journal of Nuclear Medicine

Abbreviated Title: J Nucl Med

Publisher: Society of Nuclear Medicine

ISSN (Print): 0161-5505

ISSN (Electronic): 2159-662X

Publication date Created: October 01 2014

Publication date Created: October 2014

Publication date (Print): October 2014

Publication date (Electronic): September 11 2014

Volume: 55

Issue: 10

Pages: 1591-1597

Article

DOI: 10.2967/jnumed.113.134486

PubMed ID: 25214642

SO-VID: 22240e16-8170-406f-af87-9b320257da44

History

Data availability:

Comments

Comment on this article

scite_

Cited by 19

See all cited by

Most referenced authors 349

See all reference authors

- Version 1
- Version 1

Combined PET and Biopsy Evidence of Marrow Involvement Improves Prognostic Prediction in Diffuse Large B-Cell Lymphoma

Read this article at

Abstract

Related collections

UCL: UN SDG 03 Good Health and Well-Being

Most cited references 21

Regression Models and Life-Tables

Revised response criteria for malignant lymphoma.

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project.

Author and article information

Journal

Article

History

Comments

Comment on this article

Similar content 1,132

Cited by 19

Most referenced authors 349